It is noteworthy that only 23% (5/21: 3 for ADHD, 1 for ADHD and anxiety, and 1 for anxiety) of individuals in our sample were being treated for ADHD and/or anxiety symptoms, suggesting that these conditions are under-recognized and undertreated by community providers treating individuals with FOXP1 syndrome. The gene discussed is FOXP1; the disease is attention deficit-hyperactivity disorder.